Biosergen

Opportunities for a partnership licence deal is in reach if the current patient study is successful. There is competition, which we highlight in this analysis. However, previous studies have shown that BSG005 is a very strong and potent candidate to challenge existing and competing antifungal drugs. In this analysis we highlight studies within the field of antifungals.

Biosergen has carried out a rights issue this spring and also has the opportunity to raise additional capital in November in connection with a warrant programme. The capital is expected to be sufficient for Biosergen to prepare for future phase 2 studies. Mangold has updated the price target to SEK 2.10 (3.00) in a Base case mostly affected by an increased number of shares. This leads to an upside of over 280 percent. The trigger is positive news from the patient study. In a Bear case, the fair value is SEK 1.5 per share and in a Bull case SEK 2.8 per share.